CGEM
HealthcareCullinan Therapeutics, Inc.
$9.99
$-0.13 (-1.28%)
Jan 5, 2026
Price History (1Y)
Analysis
Cullinan Therapeutics, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $590.17M. It has 111 employees and operates within the broader industry of biotechnology. The company's financial health is marked by significant losses, as evidenced by its net income (TTM) of -$216,812,992 and EBITDA of -$241,128,000. Additionally, Cullinan Therapeutics has negative profitability margins, with gross margin, operating margin, and profit margin all at 0.0%. The company's returns on equity and assets are also negative, standing at -40.2% and -26.5%, respectively. On the balance sheet side, the debt-to-equity ratio is low at 0.26, while cash levels are substantial at $332.60M. Cullinan Therapeutics' valuation metrics paint a mixed picture. The forward P/E ratio is significantly negative at -3.01, and the EV/EBITDA ratio is also negative at -1.10. In contrast, the price-to-book ratio is 1.31. Notably, the company's cash levels far exceed its debt of $1.19M.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its development products also include CLN-049, a humanized bispecific antibody in Phase 1 trial for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome, as well as measurable residual disease positive AML; and CLN-617, a fusion protein in Phase 1 trial for the treatment of solid tumors. It has a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $590.17M
- P/E Ratio
- N/A
- 52-Week High
- $13.33
- 52-Week Low
- $5.68
- Avg Volume
- 1.28M
- Beta
- -0.09
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 111